First human test for new weekly diabetes shot
Disease control
Completed
This early-stage study tested a new, long-acting injection called NEX-22A in 12 people with type 2 diabetes. The main goal was to see how the drug moves through the body and to check for any side effects. Participants received a single injection, and researchers monitored them cl…
Phase: PHASE1 • Sponsor: Nanexa AB • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC